EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation

Sunil Kaul iD, Nelson B Cole, Joanna Bandola-Simon iD, Ying Lu, Elena Tondini iD, Even Walseng, Paul A Roche iD

Proceedings of the National Academy of Sciences · 2025

DOI: 10.1073/pnas.2504077122 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Sunil Kaul und 6 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Hauptthemen laut MEDLINE: Ubiquitination, Endocytosis, Histocompatibility Antigens Class II, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH Intramural Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MHC class II glycoproteins (MHC-II) bind peptides derived from exogenous antigens and dendritic cells (DCs) present these peptide MHC-II (pMHC-II) complexes to antigen-specific CD4 T cells during immune responses. The turnover of surface pMHC-II on antigen-presenting cells (APCs) is controlled by ubiquitin-mediated degradation of pMHC-II by the E3 ubiquitin ligase March-I. To study March-I protein expression, we have generated a mouse in which a V5 epitope-tag was knocked-in to the endogenous March-I gene, thereby allowing us to follow the fate of March-I using high-affinity anti-V5 antibodies. Quantitative analysis revealed that resting spleen DCs and B cells express only ~500 and 125 March-I molecules/cell, respectively. Endogenous March-I protein has a very short half-life in DCs and March-I mRNA, March-I protein, and MHC-II ubiquitination are rapidly terminated upon activation of both DCs and B cells. Like March-I, CD83 is a known regulator of MHC-II expression in APCs and we also show that CD83 suppresses endogenous March-I-dependent MHC-II ubiquitination, endocytosis, and degradation in mouse spleen DCs. Thus, our study reveals molecular mechanisms for both March-I- and CD83-dependent regulation of MHC-II expression in APCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UbiquitinationEndocytosisHistocompatibility Antigens Class IIUbiquitin-Protein LigasesImmunoglobulinsAntigens, CDMembrane GlycoproteinsAnimalsMiceCD83 AntigenDendritic CellsProteolysisB-LymphocytesMice, Inbred C57BL

Stichwörter der Autor:innen

MHC class IIantigen presentationubiquitination

Substanzen

Histocompatibility Antigens Class IIMARCH1 protein, mouseUbiquitin-Protein LigasesCD83 AntigenImmunoglobulinsAntigens, CDMembrane Glycoproteins

Autor:innen und Institutionen

  • Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

ORCID-Profile: Sunil Kaul, Joanna Bandola-Simon, Elena Tondini, Paul A Roche

Förderung

  • NIH Intramural Research Program

Zitieren

APA

Kaul, S., Cole, N. B., Bandola-Simon, J., Lu, Y., Tondini, E., Walseng, E., & Roche, P. A. (2025). CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2504077122

Vancouver

Kaul S, Cole NB, Bandola-Simon J, Lu Y, Tondini E, Walseng E, et al. CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2504077122

BibTeX
@article{Kaul2025,
  author = {Kaul, Sunil and Cole, Nelson B and Bandola-Simon, Joanna and Lu, Ying and Tondini, Elena and Walseng, Even and Roche, Paul A},
  title = {CD83 suppresses endogenous March-I-dependent MHC class II ubiquitination, endocytosis, and degradation},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2025},
  doi = {10.1073/pnas.2504077122}
}
Kostenlos starten →